Prognostic value of albuminuria in heart failure with preserved ejection fraction: A systematic review.

Curr Probl CardiolJun 26, 2026 (epub)
Clinical ResearchCardiologyNephrology

Leandro Barbagelata, Walter Masson, Santiago Decotto et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the prognostic significance of albuminuria in adults with heart failure with preserved ejection fraction (HFpEF). The analysis included 14 studies and found that albuminuria was consistently linked to increased risks of mortality, heart failure hospitalization, and adverse cardiovascular outcomes, independent of renal function.

Key findings

  • Albuminuria was associated with higher risks of mortality and heart failure hospitalization.
  • The prognostic value of albuminuria was independent of renal function.
  • Several studies linked albuminuria to myocardial remodeling and cardiorenal dysfunction.

Why it matters

Understanding the prognostic implications of albuminuria in HFpEF can enhance risk stratification and help identify patients at higher risk for adverse outcomes, potentially guiding clinical management.

Source

PubMed · PMID 42362130

Published in Curr Probl Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.